Markers aiding the diagnosis of chondroid tumors: An immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40

APMIS

Volumn 117, Issue 7, 2009, Pages 518-525

  Daugaard, SØren ^a   Christensen, Lise H ^b   HØgdall, Estrid ^c  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Actin; Bcl 2; Calponin; CD117 (c kit); Chondroblastoma; Chondromyxoid fibroma; Chondrosarcoma; Chordoma; Cox 2; D2 40 (podoplanin); Mdm 2; Osteonectin; YKL 40

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CALPONIN; CD17 ANTIGEN; CYCLOOXYGENASE 2; OSTEONECTIN; PODOPLANIN; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN YKL 40; SMOOTH MUSCLE ACTIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; CHONDROBLASTOMA; CHONDROMYXOID FIBROMA; CHONDROSARCOMA; CHORDOMA; FIBROMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ANTIBODIES, MONOCLONAL; BONE NEOPLASMS; CALCIUM-BINDING PROTEINS; CHONDROBLASTOMA; CHONDROSARCOMA; CHORDOMA; CYCLOOXYGENASE 2; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFILAMENT PROTEINS; OSTEONECTIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-KIT; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 67651180839     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2009.02461.x     Document Type: Article

References (27)

1. Blackwell JB, Threlfall TJ, McCaul KA. Primary malignant bone tumours in Western Australia, 1972-1996. Pathology 2005 37 : 278 83.
2. Oakley GJ, Fuhrer K, Seethala RR. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis. Mod Pathol 2008 21 : 1461 69.
3. Bovée JVM, Cleton-Jansen A-M, Taminiau AHM, Hogendoorn PCW. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Oncology 2005 6 : 599 607.
4. Ringsholt M, Høgdall EVS, Johansen JS, Price PA, Christensen LH. YKL-40 protein expression in normal adult human tissues - an immunohistochemical study. J Mol Hist 2007 38 : 33 43.
5. Johansen JS, Høyer PE, Larsen LA, Price PA, Møllgård K. YKL-40 protein expression in the early developing human muscoloskeletal system. J Histochem Cytochem 2007 55 : 1213 28.
6. Fanburg-Smith JC, Bratthauer GL, Miettinen M. Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcomas: a study of 28 cases. Hum Pathol 1999 30 : 32 8.
7. Povysil C, Tomanova R, Matejovsky Z. Muscle-specific actin expression in chondroblastomas. Hum Pathol 1997 28 : 316 20.
8. Romeo S, Eyden B, Prins FA, Briaire-de Bruijn IH, Taminiau AHM, Hogendoorn PCW. TGF-β1 drives partial myofibroblastic differentiation in chondromyxoid fibroma of bone. J Pathol 2006 208 : 26 34.
9. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005 29 : 1340 7.
10. Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, et al. Activating mutations in c-kit and PDGFRα are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther 2005 4 : 1270 4.
11. Daugaard S, Myhre-Jensen O, Schiødt T, Jurik AG, Keller J, Mouridsen HT, et al. Clinical and histopathological prognostic factors in chondrosarcomas. Sarcoma 1997 1 : 47 54.
12. Huse JT, Pasha TL, Zhang PJ. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordomas. Acta Neuropathol 2007 113 : 87 94.
13. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 2006 209 : 157 65.
14. Ordoñez NG. Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol 2006 13 : 83 8.
15. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T, et al. The platelet-inducing factor Aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2006 170 : 1337 4.
16. Bovée JV, van den Broek LJ, Cleton-Jansen AM, Hogendoorn PC. Up-regulation of PTHrP and bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 2000 80 : 1925 34.
17. Hameetman L, Kok P, Eilers PHC, Cleton-Jansen AM, Hogendoorn PCW, Bovée JVMG. The use of bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 2005 446 : 430 7.
18. Fletcher CDM, Unni KK, Mertens F, editors. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France : IARC Press, 2002.
19. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002 117 : 188 93.
20. Subramanian S, West RB, Marinelli RJ, Nielsen TO, Rubin BP, Goldblum JR, et al. The gene expression profile of extraskeletal myxoid chondrosarcoma. J Pathol 2005 206 : 433 44.
21. Sjögren H, Meis-Kindblom JM, Örndal C, Bergh P, Ptaszynski K, åman P, et al. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma - cytogenetic, molecular genetic and cDNA microarray analyses. Am J Pathol 2003 162 : 781 92.
22. Adams JM, Cory S. The bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007 26 : 1324 37.
23. Kim DW, Seo SW, Cho SK, Chang SS, Lee HW, Lee SE, et al. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of grade II chondrosarcoma cells. J Orthop Res 2007 25 : 820 8.
24. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004 92 : 679 90.
25. Oshiro Y, Chaturvedi V, Hayden D, Nazeer T, Johnson M, Johnston DA, et al. Altered p53 is associated with aggressive behaviour of chondrosarcoma: a long term follow-up study. Cancer 1998 83 : 2324 34.
26. Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, et al. PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006 208 : 615 23.
27. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006 15 : 194 202.